Please use this identifier to cite or link to this item:
Title: Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I
Author: Vieira, Raquel
Souto, Selma B.
Sánchez-López, E. (Elena)
López-Machado, Ana
Severino, Patrícia
Jose, Sajan
Santini, Antonello
Fortiuna, Ana
García López, María Luisa
Silva, Amélia M.
Souto, Eliana B.
Keywords: Diabetis no-insulinodependent
Síndrome metabòlica
Non-insulin-dependent diabetes
Metabolic syndrome
Blood sugar
Issue Date: 10-Oct-2019
Publisher: MDPI
Abstract: Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed
Note: Reproducció del document publicat a:
It is part of: Pharmaceuticals, 2019, vol. 12, num. 4, p. 152
Related resource:
ISSN: 1424-8247
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
701302.pdf1.21 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons